Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey

Oholi Tovia-Brodie; Moshe Rav Acha; Bernard Belhassen; Alessio Gasperetti; Marco Schiavone; Giovanni Battista Forleo; Milton E. Guevara-Valdivia; David Valdeolivar Ruiz; Nicolas Lellouche; David Hamon; Davide Castagno; Matteo Bellettini; Gaetano M. De Ferrari; Mikael Laredo; Jean Baptiste Carvès; Barbara Ignatiuk; Giampaolo Pasquetto; Paolo De Filippo; Giovanni Malanchini; Behzad B. Pavri; Craig Raphael; Luigi Rivetti; Roberto Mantovan; Jason Chinitz; Melissa Harding; Giuseppe Boriani; Edoardo Casali; Elaine Y. Wan; Angelo Biviano; Carlos Macias; Stepan Havranek; Pietro Enea Lazzerini; Antonio M. Canu; Marco Zardini; Giulio Conte; Óscar Cano; Michela Casella; Boris Rudic; Alexander Omelchenko; Nilesh Mathuria; Gaurav A. Upadhyay; Asaf Danon; Arie Lorin Schwartz; Philippe Maury; Shiro Nakahara; Gustavo Goldenberg; Nicolas Schaerli; Sergiy Bereza; Angelo Auricchio; Michael Glikson; Yoav Michowitz

doi:10.1016/j.hrthm.2021.10.020

Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey

Oholi Tovia-Brodie, Moshe Rav Acha, Bernard Belhassen, Alessio Gasperetti, Marco Schiavone, Giovanni Battista Forleo, Milton E. Guevara-Valdivia, David Valdeolivar Ruiz, Nicolas Lellouche, David Hamon, Davide Castagno, Matteo Bellettini, Gaetano M. De Ferrari, Mikael Laredo, Jean Baptiste Carvès, Barbara Ignatiuk, Giampaolo Pasquetto, Paolo De Filippo, Giovanni Malanchini, Behzad B. PavriCraig Raphael, Luigi Rivetti, Roberto Mantovan, Jason Chinitz, Melissa Harding, Giuseppe Boriani, Edoardo Casali, Elaine Y. Wan, Angelo Biviano, Carlos Macias, Stepan Havranek, Pietro Enea Lazzerini, Antonio M. Canu, Marco Zardini, Giulio Conte, Óscar Cano, Michela Casella, Boris Rudic, Alexander Omelchenko, Nilesh Mathuria, Gaurav A. Upadhyay, Asaf Danon, Arie Lorin Schwartz, Philippe Maury, Shiro Nakahara, Gustavo Goldenberg, Nicolas Schaerli, Sergiy Bereza, Angelo Auricchio, Michael Glikson, Yoav Michowitz

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Background: Cardiac implantable electronic device (CIED) implantation rates as well as the clinical and procedural characteristics and outcomes in patients with known active coronavirus disease 2019 (COVID-19) are unknown. Objective: The purpose of this study was to gather information regarding CIED procedures during active COVID-19, performed with personal protective equipment, based on an international survey. Methods: Fifty-three centers from 13 countries across 4 continents provided information on 166 patients with known active COVID-19 who underwent a CIED procedure. Results: The CIED procedure rate in 133,655 hospitalized COVID-19 patients ranged from 0 to 16.2 per 1000 patients (P <.001). Most devices were implanted due to high-degree/complete atrioventricular block (112 [67.5%]) or sick sinus syndrome (31 [18.7%]). Of the 166 patients in the study survey, the 30-day complication rate was 13.9% and the 180-day mortality rate was 9.6%. One patient had a fatal outcome as a direct result of the procedure. Differences in patient and procedural characteristics and outcomes were found between Europe and North America. An older population (76.6 vs 66 years; P <.001) with a nonsignificant higher complication rate (16.5% vs 7.7%; P = .2) was observed in Europe vs North America, whereas higher rates of critically ill patients (33.3% vs 3.3%; P <.001) and mortality (26.9% vs 5%; P = .002) were observed in North America vs Europe. Conclusion: CIED procedure rates during known active COVID-19 disease varied greatly, from 0 to 16.2 per 1000 hospitalized COVID-19 patients worldwide. Patients with active COVID-19 infection who underwent CIED implantation had high complication and mortality rates. Operators should take these risks into consideration before proceeding with CIED implantation in active COVID-19 patients.

Original language	English (US)
Pages (from-to)	206-216
Number of pages	11
Journal	Heart Rhythm
Volume	19
Issue number	2
DOIs	https://doi.org/10.1016/j.hrthm.2021.10.020
State	Published - Feb 2022

Keywords

Active COVID-19
Cardiac implantable electronic device procedure
Complications
Mortality
Personal protective equipment

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1016/j.hrthm.2021.10.020

Cite this

Tovia-Brodie, O., Rav Acha, M., Belhassen, B., Gasperetti, A., Schiavone, M., Forleo, G. B., Guevara-Valdivia, M. E., Ruiz, D. V., Lellouche, N., Hamon, D., Castagno, D., Bellettini, M., De Ferrari, G. M., Laredo, M., Carvès, J. B., Ignatiuk, B., Pasquetto, G., De Filippo, P., Malanchini, G., ... Michowitz, Y. (2022). Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey. Heart Rhythm, 19(2), 206-216. https://doi.org/10.1016/j.hrthm.2021.10.020

Tovia-Brodie, O, Rav Acha, M, Belhassen, B, Gasperetti, A, Schiavone, M, Forleo, GB, Guevara-Valdivia, ME, Ruiz, DV, Lellouche, N, Hamon, D, Castagno, D, Bellettini, M, De Ferrari, GM, Laredo, M, Carvès, JB, Ignatiuk, B, Pasquetto, G, De Filippo, P, Malanchini, G, Pavri, BB, Raphael, C, Rivetti, L, Mantovan, R, Chinitz, J, Harding, M, Boriani, G, Casali, E, Wan, EY, Biviano, A, Macias, C, Havranek, S, Lazzerini, PE, Canu, AM, Zardini, M, Conte, G, Cano, Ó, Casella, M, Rudic, B, Omelchenko, A, Mathuria, N, Upadhyay, GA, Danon, A, Schwartz, AL, Maury, P, Nakahara, S, Goldenberg, G, Schaerli, N, Bereza, S, Auricchio, A, Glikson, M & Michowitz, Y 2022, 'Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey', Heart Rhythm, vol. 19, no. 2, pp. 206-216. https://doi.org/10.1016/j.hrthm.2021.10.020

@article{7f907add52ab42a2b6e4c5f46a49d244,

title = "Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey",

abstract = "Background: Cardiac implantable electronic device (CIED) implantation rates as well as the clinical and procedural characteristics and outcomes in patients with known active coronavirus disease 2019 (COVID-19) are unknown. Objective: The purpose of this study was to gather information regarding CIED procedures during active COVID-19, performed with personal protective equipment, based on an international survey. Methods: Fifty-three centers from 13 countries across 4 continents provided information on 166 patients with known active COVID-19 who underwent a CIED procedure. Results: The CIED procedure rate in 133,655 hospitalized COVID-19 patients ranged from 0 to 16.2 per 1000 patients (P <.001). Most devices were implanted due to high-degree/complete atrioventricular block (112 [67.5%]) or sick sinus syndrome (31 [18.7%]). Of the 166 patients in the study survey, the 30-day complication rate was 13.9% and the 180-day mortality rate was 9.6%. One patient had a fatal outcome as a direct result of the procedure. Differences in patient and procedural characteristics and outcomes were found between Europe and North America. An older population (76.6 vs 66 years; P <.001) with a nonsignificant higher complication rate (16.5% vs 7.7%; P = .2) was observed in Europe vs North America, whereas higher rates of critically ill patients (33.3% vs 3.3%; P <.001) and mortality (26.9% vs 5%; P = .002) were observed in North America vs Europe. Conclusion: CIED procedure rates during known active COVID-19 disease varied greatly, from 0 to 16.2 per 1000 hospitalized COVID-19 patients worldwide. Patients with active COVID-19 infection who underwent CIED implantation had high complication and mortality rates. Operators should take these risks into consideration before proceeding with CIED implantation in active COVID-19 patients.",

keywords = "Active COVID-19, Cardiac implantable electronic device procedure, Complications, Mortality, Personal protective equipment",

author = "Oholi Tovia-Brodie and {Rav Acha}, Moshe and Bernard Belhassen and Alessio Gasperetti and Marco Schiavone and Forleo, {Giovanni Battista} and Guevara-Valdivia, {Milton E.} and Ruiz, {David Valdeolivar} and Nicolas Lellouche and David Hamon and Davide Castagno and Matteo Bellettini and {De Ferrari}, {Gaetano M.} and Mikael Laredo and Carv{\`e}s, {Jean Baptiste} and Barbara Ignatiuk and Giampaolo Pasquetto and {De Filippo}, Paolo and Giovanni Malanchini and Pavri, {Behzad B.} and Craig Raphael and Luigi Rivetti and Roberto Mantovan and Jason Chinitz and Melissa Harding and Giuseppe Boriani and Edoardo Casali and Wan, {Elaine Y.} and Angelo Biviano and Carlos Macias and Stepan Havranek and Lazzerini, {Pietro Enea} and Canu, {Antonio M.} and Marco Zardini and Giulio Conte and {\'O}scar Cano and Michela Casella and Boris Rudic and Alexander Omelchenko and Nilesh Mathuria and Upadhyay, {Gaurav A.} and Asaf Danon and Schwartz, {Arie Lorin} and Philippe Maury and Shiro Nakahara and Gustavo Goldenberg and Nicolas Schaerli and Sergiy Bereza and Angelo Auricchio and Michael Glikson and Yoav Michowitz",

note = "Funding Information: Disclosures: Dr Lellouche has received consultant fees from Abbott, Medtronic, and Boston Scientific. Dr Chinitz has received consultant fees from Medtronic, Biosense Webster, and Boston Scientific. Dr Cano has received consultant fees from Medtronic and Boston Scientific. Dr Auricchio has received consultant fees from Boston Scientific, Backbeat, Biosense Webster, CAIRDAC, Corvia Medical, EBR Systems, MicroPort CRM, Philips, and Radcliffe Publisher; speakers{\textquoteright} fee from Boston Scientific, Medtronic, and MicroPort CRM; participated in clinical trials for Boston Scientific, EBR System, Medtronic, and Philips; and discloses intellectual properties in Boston Scientific, Biosense Webster, and MicroPort CRM. Dr Upadhyay has received consultant fees from Abbott, Biotronik, Medtronic, and Zoll Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The data underlying this article will be shared on reasonable request to the corresponding author. Funding Sources: The authors report no specific funding related to this article. Publisher Copyright: {\textcopyright} 2021 Heart Rhythm Society",

year = "2022",

month = feb,

doi = "10.1016/j.hrthm.2021.10.020",

language = "English (US)",

volume = "19",

pages = "206--216",

journal = "Heart Rhythm",

issn = "1547-5271",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Implantation of cardiac electronic devices in active COVID-19 patients

T2 - Results from an international survey

AU - Tovia-Brodie, Oholi

AU - Rav Acha, Moshe

AU - Belhassen, Bernard

AU - Gasperetti, Alessio

AU - Schiavone, Marco

AU - Forleo, Giovanni Battista

AU - Guevara-Valdivia, Milton E.

AU - Ruiz, David Valdeolivar

AU - Lellouche, Nicolas

AU - Hamon, David

AU - Castagno, Davide

AU - Bellettini, Matteo

AU - De Ferrari, Gaetano M.

AU - Laredo, Mikael

AU - Carvès, Jean Baptiste

AU - Ignatiuk, Barbara

AU - Pasquetto, Giampaolo

AU - De Filippo, Paolo

AU - Malanchini, Giovanni

AU - Pavri, Behzad B.

AU - Raphael, Craig

AU - Rivetti, Luigi

AU - Mantovan, Roberto

AU - Chinitz, Jason

AU - Harding, Melissa

AU - Boriani, Giuseppe

AU - Casali, Edoardo

AU - Wan, Elaine Y.

AU - Biviano, Angelo

AU - Macias, Carlos

AU - Havranek, Stepan

AU - Lazzerini, Pietro Enea

AU - Canu, Antonio M.

AU - Zardini, Marco

AU - Conte, Giulio

AU - Cano, Óscar

AU - Casella, Michela

AU - Rudic, Boris

AU - Omelchenko, Alexander

AU - Mathuria, Nilesh

AU - Upadhyay, Gaurav A.

AU - Danon, Asaf

AU - Schwartz, Arie Lorin

AU - Maury, Philippe

AU - Nakahara, Shiro

AU - Goldenberg, Gustavo

AU - Schaerli, Nicolas

AU - Bereza, Sergiy

AU - Auricchio, Angelo

AU - Glikson, Michael

AU - Michowitz, Yoav

N1 - Funding Information: Disclosures: Dr Lellouche has received consultant fees from Abbott, Medtronic, and Boston Scientific. Dr Chinitz has received consultant fees from Medtronic, Biosense Webster, and Boston Scientific. Dr Cano has received consultant fees from Medtronic and Boston Scientific. Dr Auricchio has received consultant fees from Boston Scientific, Backbeat, Biosense Webster, CAIRDAC, Corvia Medical, EBR Systems, MicroPort CRM, Philips, and Radcliffe Publisher; speakers’ fee from Boston Scientific, Medtronic, and MicroPort CRM; participated in clinical trials for Boston Scientific, EBR System, Medtronic, and Philips; and discloses intellectual properties in Boston Scientific, Biosense Webster, and MicroPort CRM. Dr Upadhyay has received consultant fees from Abbott, Biotronik, Medtronic, and Zoll Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The data underlying this article will be shared on reasonable request to the corresponding author. Funding Sources: The authors report no specific funding related to this article. Publisher Copyright: © 2021 Heart Rhythm Society

PY - 2022/2

Y1 - 2022/2

N2 - Background: Cardiac implantable electronic device (CIED) implantation rates as well as the clinical and procedural characteristics and outcomes in patients with known active coronavirus disease 2019 (COVID-19) are unknown. Objective: The purpose of this study was to gather information regarding CIED procedures during active COVID-19, performed with personal protective equipment, based on an international survey. Methods: Fifty-three centers from 13 countries across 4 continents provided information on 166 patients with known active COVID-19 who underwent a CIED procedure. Results: The CIED procedure rate in 133,655 hospitalized COVID-19 patients ranged from 0 to 16.2 per 1000 patients (P <.001). Most devices were implanted due to high-degree/complete atrioventricular block (112 [67.5%]) or sick sinus syndrome (31 [18.7%]). Of the 166 patients in the study survey, the 30-day complication rate was 13.9% and the 180-day mortality rate was 9.6%. One patient had a fatal outcome as a direct result of the procedure. Differences in patient and procedural characteristics and outcomes were found between Europe and North America. An older population (76.6 vs 66 years; P <.001) with a nonsignificant higher complication rate (16.5% vs 7.7%; P = .2) was observed in Europe vs North America, whereas higher rates of critically ill patients (33.3% vs 3.3%; P <.001) and mortality (26.9% vs 5%; P = .002) were observed in North America vs Europe. Conclusion: CIED procedure rates during known active COVID-19 disease varied greatly, from 0 to 16.2 per 1000 hospitalized COVID-19 patients worldwide. Patients with active COVID-19 infection who underwent CIED implantation had high complication and mortality rates. Operators should take these risks into consideration before proceeding with CIED implantation in active COVID-19 patients.

AB - Background: Cardiac implantable electronic device (CIED) implantation rates as well as the clinical and procedural characteristics and outcomes in patients with known active coronavirus disease 2019 (COVID-19) are unknown. Objective: The purpose of this study was to gather information regarding CIED procedures during active COVID-19, performed with personal protective equipment, based on an international survey. Methods: Fifty-three centers from 13 countries across 4 continents provided information on 166 patients with known active COVID-19 who underwent a CIED procedure. Results: The CIED procedure rate in 133,655 hospitalized COVID-19 patients ranged from 0 to 16.2 per 1000 patients (P <.001). Most devices were implanted due to high-degree/complete atrioventricular block (112 [67.5%]) or sick sinus syndrome (31 [18.7%]). Of the 166 patients in the study survey, the 30-day complication rate was 13.9% and the 180-day mortality rate was 9.6%. One patient had a fatal outcome as a direct result of the procedure. Differences in patient and procedural characteristics and outcomes were found between Europe and North America. An older population (76.6 vs 66 years; P <.001) with a nonsignificant higher complication rate (16.5% vs 7.7%; P = .2) was observed in Europe vs North America, whereas higher rates of critically ill patients (33.3% vs 3.3%; P <.001) and mortality (26.9% vs 5%; P = .002) were observed in North America vs Europe. Conclusion: CIED procedure rates during known active COVID-19 disease varied greatly, from 0 to 16.2 per 1000 hospitalized COVID-19 patients worldwide. Patients with active COVID-19 infection who underwent CIED implantation had high complication and mortality rates. Operators should take these risks into consideration before proceeding with CIED implantation in active COVID-19 patients.

KW - Active COVID-19

KW - Cardiac implantable electronic device procedure

KW - Complications

KW - Mortality

KW - Personal protective equipment

UR - http://www.scopus.com/inward/record.url?scp=85120168356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120168356&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2021.10.020

DO - 10.1016/j.hrthm.2021.10.020

M3 - Article

C2 - 34710561

AN - SCOPUS:85120168356

VL - 19

SP - 206

EP - 216

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 2

ER -

Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this